ClinicalTrials.gg
CompletedNCT02549040Updated Jan 7, 2021Results posted

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

A Phase 1 interventional study of Treatment A: Doravirine 100 mg film coated tablet and Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) in Human Immunodeficiency Virus-1 (HIV-1), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate and compare the relative bioavailability of different doravirine (MK-1439) experimental nano formulations (NFs) with that of a doravirine film coated tablet.

02

Conditions studied

  • Human Immunodeficiency Virus-1 (HIV-1)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy participants
  • have been a non-smoker and/or have not used nicotine or nicotine-containing products for at least approximately 3 months

Exclusion criteria

Exclusion Criteria:

  • is a pregnant or a nursing female
  • has a history of stroke, chronic seizures or major neurological disorder
  • has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
  • has a history of neoplastic disease (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Doravirine fixed sequence treatment

    After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet \[40% drug loaded granule\]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet \[30% drug loaded granule\]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet \[50% drug loaded granule\]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet \[30% drug loaded granule\]). Each period was separated by a 14 day washout.

    Drug: Treatment A: Doravirine 100 mg film coated tablet · Drug: Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) · Drug: Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) · Drug: Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) · Drug: Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439

    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.

    Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose

  2. Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439

    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.

    Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose

  3. Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439

    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.

    Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose

  4. Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439

    During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.

    Time frame: Periods 1 to 5: 24 hours post-dose

  5. Number of Participants Who Experienced at Least One Adverse Event

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

    Time frame: Up to 16 days after last dose of study treatment (up to approximately 92 days)

  6. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

    Time frame: Up to 4 days after last dose of study treatment (up to approximately 76 days)

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439

    During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.

    Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose

07

Results

Posted Feb 22, 2019

Participant flow

Period 1
Participant flow — Period 1
MilestoneMK-1439 Fixed Sequence Treatment
Started16
Completed16
Not completed0
Period 2
Participant flow — Period 2
MilestoneMK-1439 Fixed Sequence Treatment
Started16
Completed16
Not completed0
Period 3
Participant flow — Period 3
MilestoneMK-1439 Fixed Sequence Treatment
Started16
Completed16
Not completed0
Period 4
Participant flow — Period 4
MilestoneMK-1439 Fixed Sequence Treatment
Started16
Completed16
Not completed0
Period 5
Participant flow — Period 5
MilestoneMK-1439 Fixed Sequence Treatment
Started16
Completed16
Not completed0

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439

During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.

Time frame:
Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · µM*h
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439
µM*hTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-143928.6 ± 34.631.9 ± 33.935.5 ± 29.629.1 ± 30.328.0 ± 27.5
Statistical analysis
  • Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) vs Treatment A: MK-1439 100 mg Film Coated Tablet · Geometric mean ratio: 0.96 · 90% CI 0.85 to 1.09
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 1.13 · 90% CI 1.02 to 1.26
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) · Geometric mean ratio: 0.99 · 90% CI 0.88 to 1.11
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 0.89 · 90% CI 0.80 to 0.99
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439

During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.

Time frame:
Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · μM*h
Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439
μM*hTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-143926.3 ± 29.329.9 ± 31.132.7 ± 26.327.0 ± 28.426.3 ± 27.0
Statistical analysis
  • Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) vs Treatment A: MK-1439 100 mg Film Coated Tablet · Geometric mean ratio: 0.88 · 90% CI 0.79 to 0.98
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 1.09 · 90% CI 0.98 to 1.21
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) · Geometric mean ratio: 0.90 · 90% CI 0.81 to 1.00
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 0.88 · 90% CI 0.79 to 0.97
PrimaryMaximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439

During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.

Time frame:
Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · nM
Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439
nMTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-14391070 ± 26.51520 ± 32.51320 ± 27.81060 ± 27.01160 ± 24.2
Statistical analysis
  • Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) vs Treatment A: MK-1439 100 mg Film Coated Tablet · Geometric mean ratio: 0.70 · 90% CI 0.61 to 0.82
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 0.87 · 90% CI 0.75 to 1.01
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) · Geometric mean ratio: 0.70 · 90% CI 0.60 to 0.81
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 0.76 · 90% CI 0.66 to 0.86
PrimaryPlasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439

During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.

Time frame:
Periods 1 to 5: 24 hours post-dose
Reported as:
Geometric mean · nM
Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439
nMTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439395 ± 31.9483 ± 33.3508 ± 23.2412 ± 28.0402 ± 32.0
Statistical analysis
  • Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) vs Treatment A: MK-1439 100 mg Film Coated Tablet · Geometric mean ratio: 0.82 · 90% CI 0.72 to 0.93
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 1.05 · 90% CI 0.94 to 1.18
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) · Geometric mean ratio: 0.85 · 90% CI 0.76 to 0.96
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 0.83 · 90% CI 0.74 to 0.94
PrimaryNumber of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

Time frame:
Up to 16 days after last dose of study treatment (up to approximately 92 days)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Adverse Event
ParticipantsTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Number of Participants Who Experienced at Least One Adverse Event25461
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

Time frame:
Up to 4 days after last dose of study treatment (up to approximately 76 days)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
ParticipantsTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event00000
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439

During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.

Time frame:
Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose
Reported as:
Geometric mean · µM*h
Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439
µM*hTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-143922.8 ± 27.527.2 ± 29.228.8 ± 24.823.2 ± 27.323.3 ± 25.9
Statistical analysis
  • Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) vs Treatment A: MK-1439 100 mg Film Coated Tablet · Geometric mean ratio: 0.84 · 90% CI 0.75 to 0.94
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 1.06 · 90% CI 0.95 to 1.18
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) · Geometric mean ratio: 0.85 · 90% CI 0.76 to 0.95
  • Treatment A: MK-1439 100 mg Film Coated Tablet vs Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) · Geometric mean ratio: 0.86 · 90% CI 0.77 to 0.96

Adverse events

Collected over Up to 16 days following the last dose of study treatment (up to approximately 92 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)0/16 (0%)0/16 (0%)2/16 (12.5%)
Treatment A: MK-1439 100 mg Film Coated Tablet0/16 (0%)0/16 (0%)5/16 (31.3%)
Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)0/16 (0%)0/16 (0%)4/16 (25%)
Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)0/16 (0%)0/16 (0%)6/16 (37.5%)
Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)0/16 (0%)0/16 (0%)1/16 (6.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTreatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)Treatment A: MK-1439 100 mg Film Coated TabletTreatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)
HeadacheNervous system disorders1/162/162/163/160/16
NasopharyngitisInfections and infestations0/162/160/160/160/16
LacerationInjury, poisoning and procedural complications0/160/162/160/160/16
CoughRespiratory, thoracic and mediastinal disorders0/160/160/162/160/16
Vision blurredEye disorders0/161/160/160/160/16
DiarrhoeaGastrointestinal disorders0/160/161/160/161/16
ToothacheGastrointestinal disorders0/161/160/160/160/16
Feeling of body temperture changeGeneral disorders0/160/160/161/160/16
Skin abrasionInjury, poisoning and procedural complications0/160/160/161/160/16
Back painMusculoskeletal and connective tissue disorders0/160/160/161/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)MK-1439 Fixed Sequence Treatment
Mean41.8 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)MK-1439 Fixed Sequence Treatment
Female6
Male10
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Dec 2015, 3 months.

Results were first posted in Feb 2019, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2015
First posted
Sep 14, 2015
StartActual
Sep 21, 2015
Primary completionActual
Dec 24, 2015
CompletionActual
Dec 24, 2015
Results first posted
Feb 22, 2019
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02549040
Responsible party
Sponsor
First posted
Sep 14, 2015
Start date
Sep 21, 2015
Primary completion
Dec 24, 2015
Completion
Dec 24, 2015
Results posted
Feb 22, 2019
Last update
Jan 7, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion